Drug Type Bispecific antibody |
Synonyms |
Target |
Mechanism CLDN18.2 inhibitors(Claudin 18.2 inhibitors), Trop-2 inhibitors(Tumor-associated calcium signal transducer 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Biosion, Inc.Startup |
Active Organization Biosion, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | CN | Biosion, Inc.Startup | 02 Nov 2023 |